A synthetic cationic innate defense regulator peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

IDR 1002 (trifluoroacetate salt)

Item No. 36893

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-valyl-L-glutaminyl-L-arginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-valyl-L-tryptophyl-L-arginyl-L-isoleucyl-L-arginyl-L-lysinamide, trifluoroacetate salt
Molecular Formula
C79H130N26O13 • XCF3COOH
Formula Weight
1652.0
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Slightly solublePBS (pH 7.2): Slightly soluble
SMILES
NCCCC[C@@H](C(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@@H](N)C(C)C)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=O.OC(C(C)(F)F)=O
InChi Code
InChI=1S/C79H130N26O13.C3H4F2O2/c1-11-44(9)63(75(117)99-54(28-20-34-91-78(86)87)66(108)95-52(65(83)107)26-17-18-32-80)104-69(111)55(29-21-35-92-79(88)89)97-70(112)59(38-47-40-94-51-25-16-14-23-49(47)51)102-74(116)62(43(7)8)103-76(118)64(45(10)12-2)105-72(114)57(36-41(3)4)100-71(113)58(37-46-39-93-50-24-15-13-22-48(46)50)101-67(109)53(27-19-33-90-77(84)85)96-68(110)56(30-31-60(81)106)98-73(115)61(82)42(5)6;1-3(4,5)2(6)7/h13-16,22-25,39-45,52-59,61-64,93-94H,11-12,17-21,26-38,80,82H2,1-10H3,(H2,81,106)(H2,83,107)(H,95,108)(H,96,110)(H,97,112)(H,98,115)(H,99,117)(H,100,113)(H,101,109)(H,102,116)(H,103,118)(H,104,111)(H,105,114)(H4,84,85,90)(H4,86,87,91)(H4,88,89,92);1H3,(H,6,7)/t44-,45-,52-,53-,54-,55-,56-,57-,58-,59-,61-,62-,63-,64-;/m0./s1
InChi Key
UZQFRGFLFPQJGO-NEORNSIFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $86

    Add

    10 mg

    $154

    Add

    25 mg

    $363

    Add

    50 mg

    $684

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    IDR 1002 is a synthetic cationic innate defense regulator peptide.1 It increases the production of chemokine (C-C motif) ligand 2 (CCL2), CCL7, and chemokine (C-X-C motif) ligand 1 (CXCL1) in isolated human peripheral blood mononuclear cells (PBMCs) when used at a concentration of 100 µg/ml. IDR 1002 (200 µg/animal) increases the numbers of neutrophils and monocytes in mouse peritoneum and protects against S. aureus and E. coli infections in mice.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nijnik, A., Madera, L., Ma, S., et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. immunol. 184(5), 2539-2550 (2010).